Clinical trials: Carcinoma, Transitional Cell
Metastatic Cancer, Urothelial Carcinoma
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
A nonrandomized phase II trial is proposed combining avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin as switch maintenance therapy for mUC following stable or responding disease on 4-6 cycles of first line platinum-based…
- Trial name
- NCT05574504
- Testing
- avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin
- Where
- United States
- Sponsor
- AdventHealth
Metastatic Urothelial Carcinoma, Bladder Cancer
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
This is an open label, non-randomized phase 2 study of the combination of pembrolizumab and cabozantinib to assess overall response rate (ORR), progression free survival at 6 months (PFS6), and overall survival (OS) in patients…
- Trial name
- PemCab (NCT03534804)
- Testing
- Cabozantinib, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Utah
Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
Urothelial carcinomas are one of the most commonly diagnosed cancers worldwide. Postoperative patients carry a poor prognosis with an estimated five-year disease-specific survival rate of 50%.
- Trial name
- NCT06257017
- Testing
- gemcitabine, Cisplatin
- Where
- Hong Kong
- Volunteers
- 15 people
- Sponsor
- Yung NA
Urothelial Carcinoma (UC)
Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors
This study is an open-label, single-arm, interventional clinical trial designed to investigate the safety of ⁶⁸Ga/¹⁷⁷Lu-BRP-020063 in patients with advanced metastatic solid tumors; to evaluate the pharmacokinetics…
- Trial name
- NCT07439120
- Testing
- ⁶⁸Ga/¹⁷⁷Lu-BRP-020063
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Urothelial Carcinoma
BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
BIBF1120 in patients with advanced FGFR3 mutated, FGFR3 overexpressed, or FGFR3 wild type urothelial carcinoma of urinary bladder, urethra, ureter, and renal pelvis and who have failed platinum-based chemotherapy.
- Trial name
- NCT02278978
- Testing
- BIBF1120
- Where
- Taiwan
- Volunteers
- 129 people
- Sponsor
- National Taiwan University Hospital
High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma, Perfusion; Complications
Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma
To evaluate the effect of hyperthermic intravesical perfusion on the risk of intraoperative implantation of muscle-invasive bladder urothelial carcinoma and its safety.
- Conditions
- High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma, Perfusion; Complications, Intraoperative Complications
- Trial name
- NCT05276167
- Testing
- hyperthermic intravesical perfusion
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
Renal Cell Carcinoma, Renal Cysts
Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial
To compare SBDECT with standard Triple Phase Multi-Detector CT (TPMDCT) in renal mass evaluation in terms of appropriateness of treatment received after diagnosis. To determine SBDECT diagnostic accuracy.
- Conditions
- Renal Cell Carcinoma, Renal Cysts, Transitional Cell Carcinoma, AML
- Trial name
- NCT02160600
- Testing
- Standard multiphase CT, split bolus Dual energy CT
- Where
- India
- Volunteers
- 124 people
- Sponsor
- All India Institute of Medical Sciences
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma
Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery
This pilot clinical trial studies how well gemcitabine hydrochloride, cisplatin, and AGS-003-BLD work in treating patients with bladder cancer that has spread to the muscle and who are undergoing surgery.
- Conditions
- Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma
- Trial name
- NCT02944357
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Radical Cystectomy
- Where
- United States
- Sponsor
- Mayo Clinic
Transitional Cell Carcinoma
Detecting Transitional Cell Carcinoma From Haematuria
To validate ELISAs for the detection of urinary tissue factor (TF) in patients suspected of having bladder cancer.
- Trial name
- TransTuFo (NCT03256877)
- Where
- United Kingdom
- Volunteers
- 750 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Bladder Cancer, Bladder Neoplasm
Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct)
A bicentric, open-label randomised controlled trial (RCT) is planned to investigate whether the use of fitness wristbands in a defined preoperative period prior to radical cystectomy leads to a preoperative increase in…
- Conditions
- Bladder Cancer, Bladder Neoplasm, Bladder Urothelial Carcinoma
- Trial name
- PreAct (NCT06416319)
- Testing
- Daily Activity Goal and Feedback
- Where
- 2 sites in Germany
- Volunteers
- 164 people
- Sponsor
- Universitätsmedizin Mannheim
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors.
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- IMAGINE (NCT04637594)
- Testing
- Pembrolizumab, Nivolumab, Atezolizumab
- Where
- 377 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma
DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC
Approximately 20 participants will be enrolled in the study to evaluate the efficacy and safety of the combination of DV (DV, 2.0 mg/kg, intravenously administered every 2 weeks) and toripalimab (toripalimab, 3.0mg/kg…
- Conditions
- Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma, Solitary Kidney
- Trial name
- NCT06354231
- Testing
- DV, Toripalimab, Laser surgery
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Carcinoma, Transitional Cell
Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract
Gemcitabine plus cisplatin have been the most studied and used anticancer agents in patients with local advanced and/or metastatic transitional cell carcinoma of urothelial tract even if clinical benefits and survival remains…
- Trial name
- NCT03051373
- Testing
- nanoparticle albumin-bound paclitaxel, S-1, Gemcitabine, cisplatin
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Chinese PLA General Hospital
Urothelial Carcinoma
A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with locally advanced or metastatic HER2-negative urothelial cancer.
- Trial name
- NCT04073602
- Testing
- RC48-ADC
- Where
- China
- Volunteers
- 19 people
- Sponsor
- RemeGen Co., Ltd.
Metastatic Transitional Cell Cancer of the Urothelial Tract
Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract
The purpose of this non-randomized Phase II trial was to evaluate the efficacy of a combination of docetaxel and oxaliplatin in patients with metastatic transitional cell cancer (TCC) of the urothelial tract.
- Trial name
- NCT03159143
- Testing
- Docetaxel, Oxaliplatin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Leonard Appleman
Urothelial Cancer, Metastatic Urothelial Carcinoma
Sacituzumab Govitecan Plus EV in Metastatic UC
Phase I of this research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic urothelial carcinoma (mUC).
- Conditions
- Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
- Trial name
- NCT04724018
- Testing
- Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Dana-Farber Cancer Institute
Non-muscle-invasive Bladder Cancer, NMIBC
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.
- Conditions
- Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms
- Trial name
- NCT05483868
- Testing
- AU-011, AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration
- Where
- 19 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- Aura Biosciences
Non-muscle Invasive Bladder Cancer (NMIBC)
LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the Bladder
This study is a phase IIA, single-site, randomized, controlled, open-label clinical trial evaluating the safety and efficacy of the LCS103 oral herbal formula for the secondary prevention of NMIBC.
- Trial name
- LCS103 (NCT07728474)
- Testing
- LCS103
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- LifeBiotic Medical Research Ltd.
Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4…
- Conditions
- Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms
- Trial name
- NCT04561362
- Testing
- BT8009, Pembrolizumab
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 329 people
- Sponsor
- BicycleTx Limited
Muscle-invasive Bladder Urothelial Carcinoma
A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer
This is a prospective, open-label, single-center, single-arm clinical study. Plans to enroll 45 MIBC patients with clinical stage T2-T4aN0M0 and HER2-positive (IHC 1+/2+/3+) status.
- Trial name
- NCT07279597
- Testing
- RC48-ADC + Toripalimab
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.